Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00406367 · ClinicalTrials.gov registry record · Phase 3
IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Blepharospasm
A Phase 3 study of Blepharospasm, sponsored by Merz Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 109
- Enrollment target
- 2
- Study locations
NCT00406367 is a Phase 3 study of Blepharospasm that has completed, run by Merz Pharmaceuticals. The registered enrollment target is 109 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT00406367, a Phase 3 study of Blepharospasm, has completed, sponsored by Merz Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 109 participants
- Enrollment target
- 2
- Study locations
Study Summary
Patients received one injection with incobotulinumtoxinA (Xeomin) or placebo at baseline. Thereafter, all patients who entered the Open-Label Extension Period (OLEX) received up to five injection sessions of incobotulinumtoxinA (Xeomin) during the OLEX period.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG incobotulinumtoxinA (Xeomin)
Study Locations (2)
Texas
- Baylor College of Medicine - Houston
Nova Scotia
- David King, MD - Private Practice - Halifax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2006-10 |
| Est. Completion | 2009-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00406367
The ClinicalTrials.gov registry entry for NCT00406367 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 109 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merz Pharmaceuticals, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Blepharospasm appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00406367 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Texas, Nova Scotia.
Frequently Asked Questions
What is clinical trial NCT00406367 about?
NCT00406367 is a clinical study titled "IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Blepharospasm". Patients received one injection with incobotulinumtoxinA (Xeomin) or placebo at baseline. Thereafter, all patients who entered the Open-Label Extension Period (OLEX) received up to five injection sessions of incobotulinumtoxinA (Xeomin) during the OLEX period.
What is the current status of trial NCT00406367?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 109 participants. The study started on 2006-10. Estimated completion is 2009-07.
What conditions does trial NCT00406367 study?
This clinical trial studies the following conditions: Blepharospasm.
What interventions are being tested in trial NCT00406367?
The interventions under investigation include: Placebo (DRUG), incobotulinumtoxinA (Xeomin) (DRUG).
Who is sponsoring clinical trial NCT00406367?
This trial is sponsored by Merz Pharmaceuticals, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00406367 being conducted?
This trial has 2 study locations across Texas, Nova Scotia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Blepharospasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.